Aurinia Pharmaceuticals AUPH Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Concentration risk percentage by Product | |||||
| Collaboration partnership | 7%-4.0pp | 11%+1.0pp | 10%-10.0pp | 20%— | |
| Specialty pharmacy A | 49%0.0pp | 49%-2.0pp | 51%+6.0pp | 45%— | |
| Specialty pharmacy B | 38%-1.0pp | 39%-1.0pp | 40%+5.0pp | 35%— | |
| Revenue by Geography | |||||
| Japan | $19.21M-23.3% | $25.04M+42.6% | $17.56M-44.2% | $31.48M— | |
| U.S. | $263.84M+25.6% | $210.1M+33.0% | $157.96M+54.2% | $102.46M+125% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Aurinia Pharmaceuticals break its business down?
- Aurinia Pharmaceuticals (AUPH) reports concentration risk percentage by product across 3 parts — Collaboration partnership, Specialty pharmacy A and Specialty pharmacy B. Each is extracted from the segment footnotes and tracked over time.
- Where does Aurinia Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Aurinia Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.